Stockscreener 앱 받기
1.93
1.53%
-0.03
시간 외 거래:
1.93
전일 마감가:
$1.96
열려 있는:
$1.89
하루 거래량:
27,032
Relative Volume:
0.78
시가총액:
$29.30M
수익:
-
순이익/손실:
$-16.26M
주가수익비율:
-1.6337
EPS:
-1.1814
순현금흐름:
$-13.50M
1주 성능:
-1.03%
1개월 성능:
-12.67%
6개월 성능:
-48.53%
1년 성능:
-58.58%
1일 변동 폭
$1.8071
$1.99
1주일 범위
$1.8071
$2.0691
52주 변동 폭
$1.50
$5.275
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
1.93 | 29.30M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
INTENSITY THERAPEUTICS Earnings Results: $INTS Reports Quarterly Earnings - Nasdaq
Small Number of Acne Products Recalled for Problematic Levels of Benzene - 69News WFMZ-TV
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - PR Newswire
Intensity Therapeutics Doubles R&D Investment as Cancer Trials Gain Momentum - Stock Titan
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR.com
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas - BioSpace
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
AMC Networks (AMCX) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients - Managed Healthcare Executive
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Xylem (XYL) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):